A Phase I Dose Escalation of MK0457 [VX 680, tozasertib] in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2014
At a glance
- Drugs Dasatinib (Primary) ; Tozasertib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck & Co
- 19 Nov 2007 Status changed from initiated to suspended.
- 10 Aug 2007 New trial record.